BridgeBio Beats Earnings While CEO Dumps $1.4 Million
BridgeBio Pharma beat Q3 earnings by 25.1% after three consecutive misses, with Attruby's commercial ramp driving 192.6% revenue growth. Yet insiders sold $4.56M in stock with no offsetting purchases,
BridgeBio Q3 Beat Breaks Three-Quarter Miss Streak
NEW YORK, November 7 —
BridgeBio Pharma, Inc. (BBIO) snapped three consecutive double-digit EPS misses in Q3 2026 with a 25.1% positive surprise, yet the CEO spent August and September selling shares at $69, $85, all above the stock's current $74.29, while the chief accounting officer sold the day after earnings. The question is not whether Attruby is working. The question is what the people who built it know that the sell-side does not.
- TTM revenue of $0.95B reflects 192.6% growth, driven by Attruby's commercial ramp; gross margin is 94.3%.
- Net insider activity over 90 days: $0 in purchases versus $4.56M in open-market sales.
The Three-Quarter Hole Attruby Just Climbed Out Of
BridgeBio Pharma, the Palo Alto-based genetic medicines company, makes Attruby, an oral near-complete TTR stabilizer for transthyretin-mediated amyloidosis cardiomyopathy, a rare and historically underdiagnosed heart disease with a large addressable population. Revenue tripling in a year reflects genuine launch momentum, not noise. The three prior quarters told a different story: EPS misses of 51.3%, 35.7%, and 34.3% against consensus, suggesting commercialization costs were running ahead of revenue.
The Selling Pattern the Beat Does Not Explain
CEO Neil Kumar conducted open-market sales across August 18-19 at $81.15, $85.65 and again on September 17 at $69.01, $69.57, per Form 4 filings. His largest single transaction was 17,279 shares at $82.21, worth approximately $1.42M. Those sales followed a shelf registration filed July 24 and a 424B7 prospectus supplement on August 14, capital markets activity that preceded the selling by days. Chief Accounting Officer Maricel Apuli then sold 2,000 shares at $72.85 on October 30, the day after Q3 earnings landed. Zero shares were purchased by any insider across the entire 90-day window. Analyst consensus sits at $106.85, implying 44% upside from current levels, which makes the absence of a single insider buy the most consequential data point in this filing set.
| Ticker | Mkt cap | Fwd P/E | 52-wk |
|---|---|---|---|
| BBIO | $14.5B | n/a | +18.3% |
| DNLI | $3.2B | n/a | +28.7% |
| IMVT | $6.3B | n/a | +30.6% |
| MDGL | $9.3B | 41.5x | -19.4% |
| CYTK | $7.5B | n/a | -13.7% |
| KRYS | $8.9B | 32.6x | +50.8% |
What Needs to Be True for Either Side to Be Right
The bear case does not require Attruby to fail, only that the path to profitability is longer than consensus models. Free cash flow was -$287M on a trailing basis against $3.38B in total debt and $1.54B cash, a gap the 94.3% gross margin alone cannot close quickly. Short interest at 11.4% of float reflects that asymmetry. The bull case requires the Q3 beat to be a durable inflection rather than a one-quarter noise event: the confirming number next quarter would be EPS moving closer to breakeven, not just another beat against a sandbagged estimate. BridgeBio's pipeline, infigratinib, Encaleret, and BBP-418 across three Phase 3 programs, provides optionality, but optionality costs cash. Run the free BridgeBio Pharma, Inc. deep-dive →
Current fundamentals, valuation and filing history for BridgeBio Pharma, Inc. (BBIO) are tracked on its Basis Report page.
Basis Report is independent research for informational purposes. It is not investment advice and not a recommendation to buy or sell any security.
Frequently Asked Questions
Did BridgeBio beat Q3 earnings?
Yes. BridgeBio's Q3 EPS of -$0.42 beat the -$0.557 consensus estimate by 25.1%, ending three consecutive quarters of misses ranging from 34.3% to 51.3%.
How much did BridgeBio's CEO sell?
CEO Neil Kumar sold approximately $1.42M in shares, with his largest transaction being 17,279 shares at $82.21. He sold in August at $81, $85 and again in September at $69, all above the current stock price of $74.29.
What does BridgeBio's Attruby drug do?
Attruby is an oral near-complete TTR stabilizer for transthyretin-mediated amyloidosis cardiomyopathy, a rare and historically underdiagnosed heart disease. The drug's commercial ramp is driving BridgeBio's TTM revenue growth of 192.6% to $0.95B, with gross margin at 94.3%.
Is BridgeBio profitable?
No. Trailing free cash flow is -$287M against $3.38B in total debt and $1.54B in cash. While gross margin is strong at 94.3%, the path to profitability may take longer than consensus expects.
What are the bull and bear cases for BridgeBio?
The bull case requires the Q3 beat to be a durable inflection, with Q4 showing EPS moving closer to breakeven rather than just beating a sandbagged estimate. The bear case does not require Attruby to fail, only that the path to profitability is longer than consensus models assume, given free cash flow of -$287M against $3.38B in debt.
BridgeBio Pharma reported Q3 2026 results on October 29 showing its first EPS beat in four consecutive quarters — actual EPS of -$0.42 against an estimate of -$0.557, a 25.1% positive surprise — as trailing revenue surged 192.6%. The beat snaps three straight double-digit misses, yet the CEO sold shares at prices well above where the stock trades today and the chief accounting officer sold the day after the earnings release.